Trials / Completed
CompletedNCT00034827
A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer
A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung Cancer, Breast Cancer, Colon Cancer, or Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 172 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
CI-1040 is an experimental drug that is being tested in patients who have advanced colorectal and lung cancer who failed no more than one prior chemotherapy regimen, breast cancer who have failed no more than 2 prior regimens and in patients with pancreatic cancer who have received no prior chemotherapy. CI-1040 is taken orally twice daily with meals. Patients are required to have blood tests periodically while receiving treatment and will be monitored closely throughout the trial for possible side effects and for response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CI-1040 |
Timeline
- Start date
- 2002-01-01
- Completion
- 2003-05-01
- First posted
- 2002-05-03
- Last updated
- 2007-05-04
Locations
30 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00034827. Inclusion in this directory is not an endorsement.